• Company
• AZ runs a neurofibromatosis disease awareness campaign
• by Jung, Sae-Im May 22, 2023 05:42am

• Company
• Hana Pharm, signed a sub-license agreement for Byfav
• by Lee, Seok-Jun May 22, 2023 05:42am

• Policy
• Myelofibrosis tx BMS Inrebic to be covered from June
• by Lee, Tak-Sun May 22, 2023 05:42am

• Company
• New formulations for schizophrenia are being commercialized
• by Eo, Yun-Ho May 22, 2023 05:42am

• Company
• “Need to increase support for new AI drugs in Korea”
• by Jung, Sae-Im May 22, 2023 05:42am

• Policy
• Vemlidy’s price 4.7% ↓...Vemliver’s voluntarily 12.6% ↓
• by Kim, Jung-Ju May 22, 2023 05:42am

• Company
• Attempts to develop new drugs for hypertension
• by Hwang, Jin-joon May 22, 2023 05:41am

• Company
• Forxiga price cut enforcement suspension extended
• by Jung, Sae-Im May 19, 2023 05:48am

• Company
• HLB applies for liver cancer drug approval to FDA
• by Lee, Seok-Jun May 19, 2023 05:47am

• Company
• Korean pharma industry expands R&D investments
• by Chon, Seung-Hyun May 19, 2023 05:47am